definiens: ) in which any Public Disclosure ( as defined below)is made, [COMPANY] shall pay Crescendo royalties with respect tosales of Doxil - Registered Trademark- in the United States asfollows : ( i ) in the Initial Quarter and the following threecalendar quarters, the greatest of ( 1 ) 2.5 % of Excess NetSales ( as defined below ), ( 2 ) 1 % of Excess Net Sales plus anadditional 0.1 % of such Excess Net Sales for each full onemillion dollars of Development Payments paid by Crescendo or(3 ) 1 % of Net Sales ( as defined in the DevelopmentAgreement ) ; and ( ii ) in each subsequent calendar quarter, the greatest of ( 1 ) 3.0 % of Excess Net Sales ( as definedbelow ), ( 2 ) 1 % of Excess Net Sales plus an additional 0.1%of such Excess Net Sales for each full one million dollarsof Development Payments paid by Crescendo or ( 3 ) 1 % of NetSales